Table 8.

Association of anti-TIF1γ/α antibodies with malignancy in adult DM

Author	Country (year (n))	Prevalence of anti-TIF1γ/α in cancer-DM vs. non-cancer DM	Prevalence of malignancy in anti-TIF1γ/α (+) DM vs. (−) DM
Targoff [7]	USA (2006 (45))	100 vs. 21 % (P=0.0004)	43 vs. 0 % (P=0.0004)
Kaji [99]	Japan (2007 (52))	50 vs. 4 % (P=0.0017)	71 vs. 11 % (P=0.0017)
Chinoy [27]	UK (2007 (103))	53 vs. 13 % (P=0.0009)	42 vs. 8 % (P=0.0009)
Gunawardena [97]	UK (2008 (20))	100 vs. 18 % (P=0.0175)	50 vs. 0 % (P=0.0175)
Fujikawa [82]	Japan (2009 (30))	100 vs. 0 % (P<0.0001)	100 vs. 0 % (P<0.0001)
Kang [100]	South Korea (2010 (38))	56 vs. 10 % (P=0.0101)	63 vs. 13 % (P=0.0101)
Trallero-Araguas [98]	Spain 2010 (65)	71 vs. 10 % (P<0.0001)	67 vs. 8 % (P<0.0001)
Hamaguchi [74]	Japan (2011 (376))	44 vs. 2 % (P<0.0001)	68 vs. 6 % (P<0.0001)
Ikeda [101]	Japan (2011 (55))	22 vs. 14 % (ns)	44 vs. 30 % (ns)